… Lilly and ProQR to Expand RNAEditing Collaboration New agreement supports the discovery … in September 2021, applied ProQR’s proprietary Axiomer® RNAediting platform to target disorders of the liver and …
Platform demonstrates robust in vivo editing capabilities reporting up to 70% editing of ACTB in the liver of non-human primates (NHPs) and miceFunctional effect demonstrated in mice in vivo via modulation of ANGPLT3 protein properties leading to favora
… ProQR to Present its Axiomer® RNAEditing Technology at the Oligonucleotide and Peptide … to changing lives through the creation of transformative RNA therapies, today announced a presentation at the …
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it will present new preclinical data for its proprietary Axiomer™ RNA editing